Low relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry

Basit Öğe Kaydı
dc.contributor.authorAlibaz Öner, Fatma
dc.contributor.authorKeleşoğlu, Bahar
dc.contributor.authorBalcı, Mehmet Ali
dc.contributor.authorYardımcı, Gözde Kübra
dc.contributor.authorArmağan, Berkan
dc.contributor.authorKılıç, Levent
dc.contributor.authorKarakaş, Özlem
dc.contributor.authorErden, Abdulsamet
dc.contributor.authorYaşar Bilge, Şule
dc.contributor.authorKardaş, Rıza Can
dc.contributor.authorKüçük, Hamit
dc.contributor.authorZengin, Orhan
dc.contributor.authorTaşçı, Murat
dc.contributor.authorKocaer, Sinem Burcu
dc.contributor.authorYavuz, Şule
dc.contributor.authorDoğru, Atalay
dc.contributor.authorŞahin, Mehmet
dc.contributor.authorBayındır, Özün
dc.contributor.authorSevik, Gizem
dc.contributor.authorErtürk, Zeynep
dc.contributor.authorAlpay Kanıtez, Nilüfer
dc.contributor.authorGöğebakan, Hasan
dc.contributor.authorTezcan, Mehmet Engin
dc.contributor.authorÖksüz, Mustafa Ferhat
dc.contributor.authorÇefle, Ayşe
dc.contributor.authorKüçükşahin, Orhan
dc.contributor.authorYazıcı, Ayten
dc.contributor.authorKasapoğlu, Esen
dc.contributor.authorBeş, Cemal
dc.contributor.authorÜnal, Ali Uğur
dc.contributor.authorDalkılıç, Ediz
dc.contributor.authorYıldırım Çetin, Gözde
dc.contributor.authorAksu, Kenan
dc.contributor.authorKeser, Gökhan
dc.contributor.authorÖnen, Fatoş
dc.contributor.authorÇobankara, Veli
dc.contributor.authorKısacık, Bünyamin
dc.contributor.authorOnat, Ahmet Mesut
dc.contributor.authorÖztürk, Mehmet Akif
dc.contributor.authorKaşifoğlu, Timuçin
dc.contributor.authorOmma, Ahmet
dc.contributor.authorKaradağ, Ömer
dc.contributor.authorAteş, Aşkın
dc.contributor.authorDireskeneli, Haner
dc.date.accessioned2024-05-29T11:11:56Z
dc.date.available2024-05-29T11:11:56Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractObjective Glucocorticoids (GC) are widely accepted as the standard first-line treatment for giant cell arteritis (GCA). However, relapse rates are reported up to 80% on GC-only protocol arms in controlled trials of tocilizumab and abatacept in 12-24 months. Herein, we aimed to assess the real-life relapse rates retrospectively in patients with GCA from Turkey. Methods We assembled a retrospective cohort of patients with GCA diagnosed according to ACR 1990 criteria from tertiary rheumatology centres in Turkey. All clinical data were abstracted from medical records. Relapse was defined as any new manifestation or increased acute-phase response leading to the change of the GC dose or use of a new therapeutic agent by the treating physician. Results The study included 330 (F/M: 196/134) patients with GCA. The mean age at disease onset was 68.9±9 years. The most frequent symptom was headache. Polymyalgia rheumatica was also present in 81 (24.5%) patients. Elevation of acute phase reactants (ESR>50 mm/h or CRP>5 mg/l) was absent in 25 (7.6%) patients at diagnosis. Temporal artery biopsy was available in 241 (73%) patients, and 180 of them had positive histopathological findings for GCA. For remission induction, GC pulses (250-1000 methylprednisolone mg/3-7 days) were given to 69 (20.9%) patients, with further 0.5-1 mg/kg/day prednisolone continued in the whole group. Immunosuppressives as GC-sparing agents were used in 252 (76.4%) patients. During a follow-up of a median 26.5 (6-190) months, relapses occurred in 49 (18.8%) patients. No confounding factor was observed in relapse rates. GC treatment could be stopped in only 62 (23.8%) patients. Additionally, GC-related side effects developed in 64 (24.6%) patients, and 141 (66.2%) had at least one Vasculitis Damage Index (VDI) damage item present during follow-up. Conclusion In this first multi-centre series of GCA from Turkey, we observed that only one-fifth of patients had relapses during a mean follow-up of 26 months, with 76.4% given a GC-sparing IS agent at diagnosis. At the end of follow-up, GC-related side effects developed in one-fourth of patients. Our results suggest that patients with GCA had a low relapse rate in real-life experience of a multi-centre retrospective Turkish registry, however with a significant presence of GC-associated side effects during follow-up.
dc.identifier.citationAlibaz Öner, F., Keleşoğlu, B., Balcı, M. A., Yardımcı, G. K., Armağan, B., Kılıç, L. ... Direskeneli, H. (2024). Low relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry. Clinical and Experimental Rheumatology, 42(4), 816-821. http://dx.doi.org/10.55563/clinexprheumatol/zr7s0g
dc.identifier.doi10.55563/clinexprheumatol/zr7s0g
dc.identifier.endpage821
dc.identifier.issn0392-856X
dc.identifier.issue4
dc.identifier.pmid37976117
dc.identifier.scopus2-s2.0-85191899080
dc.identifier.scopusqualityQ2
dc.identifier.startpage816
dc.identifier.urihttp://dx.doi.org/10.55563/clinexprheumatol/zr7s0g
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12531
dc.identifier.volume42
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorErtürk, Zeynep
dc.language.isoen
dc.relation.ispartofClinical and Experimental Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGiant Cell Arteritis
dc.subjectGlucocorticoid Sparing Agents
dc.subjectGlucocorticoids
dc.subjectRelapse Rate
dc.titleLow relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Ertürk-Zeynep-2024.pdf
Boyut:
436.57 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu